Advertisement
Advertisement
U.S. Markets close in 4 hrs 14 mins
Advertisement
Advertisement
Advertisement
Advertisement

ZIVO Bioscience, Inc. (ZIVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.9100+0.1300 (+3.44%)
As of 11:44AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.7800
Open3.9164
Bid4.0000 x 1100
Ask4.0100 x 1100
Day's Range3.8000 - 4.0500
52 Week Range2.3700 - 7.9000
Volume9,709
Avg. Volume13,301
Market Cap36.831M
Beta (5Y Monthly)0.00
PE Ratio (TTM)N/A
EPS (TTM)-1.2100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Zivo Bioscience Joins Russell Microcap® Index

    BLOOMFIELD HILLS, Mich., June 27, 2022--ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that, effective today, June 27, 2022, it has joined the Russell Microcap® Index (^RUMIC) as a result of the 2022 Russell indexes annual reconstitution.

  • Business Wire

    Zivo Bioscience Regains Compliance Following Receipt of Noncompliance Notice from Nasdaq

    BLOOMFIELD HILLS, Mich., April 25, 2022--ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that it received a Notice from Nasdaq that the Company has regained compliance of Nasdaq Listing Rule 5250(c)(1).

  • Business Wire

    ZIVO Bioscience Names Chairman John B. Payne as President and CEO

    KEEGO HARBOR, Mich., January 10, 2022--ZIVO Bioscience, Inc. (NASDAQ: ZIVO) ("ZIVO" or the "Company"), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces that Chairman of the Board John B. Payne has been named President and Chief Executive Officer of the Company. Mr. Payne succeeds Andrew A. Dahl.

Advertisement
Advertisement